guest ::
| Home > Publications database > Lenvatinib as Salvage Therapy in Advanced and Progressive GI-NET. > print |
| Home > Publications database > Lenvatinib as Salvage Therapy in Advanced and Progressive GI-NET. > print |
| 001 | 303371 | ||
| 005 | 20250822113120.0 | ||
| 024 | 7 | _ | |a 10.1530/ERC-25-0165 |2 doi |
| 024 | 7 | _ | |a pmid:40748172 |2 pmid |
| 024 | 7 | _ | |a 1351-0088 |2 ISSN |
| 024 | 7 | _ | |a 1479-6821 |2 ISSN |
| 024 | 7 | _ | |a altmetric:180136439 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01620 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Mathew, A. |0 0000-0003-0244-3510 |b 0 |
| 245 | _ | _ | |a Lenvatinib as Salvage Therapy in Advanced and Progressive GI-NET. |
| 260 | _ | _ | |a Bristol |c 2025 |b Soc. for Endocrinology |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1755855041_6500 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2025 Aug 20;32(8):e250165 |
| 520 | _ | _ | |a The efficacy of lenvatinib in treating gastrointestinal neuroendocrine tumors (GI-NET) has been explored in preclinical studies and early-phase clinical trials but real-world data remains limited. Data of sixteen patients (median age 65 years; 62.5% female) with advanced and progressive GI-NET who were treated with lenvatinib at the ENETS Center, University Hospital Essen, between 07/2019 and 02/2024 were analyzed. Patients had received all other approved therapies and showed progression within two months. Salvage therapy with lenvatinib was initiated after approval by health insurance. Most NETs originated in the small intestine (94%) with a median Ki-67 index of 3.5%. Before lenvatinib, patients had received a median of four lines of treatment (range 3-7), including somatostatin analogues (100%), everolimus (100%), chemotherapy (25%) and PRRT (88%). Surgery of the primary and/or metastatic lesions was performed in 81% and ablative therapies in 38%. The median time between NET diagnosis and initiation of lenvatinib was 100 months. The overall response rate on salvage therapy was 29% and the clinical benefit rate 100%. Median progression-free survival (PFS) on lenvatinib was 10 months and median overall survival (OS) after initiation of lenvatinib reached 113 months. Hypertension was associated with significantly longer PFS (24.5 months, p=0.007), whereas weight loss correlated with shorter PFS (4 months, p=0.0032). In this retrospective single-center case analysis, lenvatinib demonstrated promising results in heavily pre-treated and rapidly progressing GI-NET. With an OS of 9.4 years after start of salvage therapy, these results highlight the value of lenvatinib as a therapeutic option for advanced GI-NET patients with otherwise limited treatment alternatives. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a NET |2 Other |
| 650 | _ | 7 | |a TKI |2 Other |
| 650 | _ | 7 | |a lenvatinib |2 Other |
| 650 | _ | 7 | |a neuroendocrine tumors |2 Other |
| 700 | 1 | _ | |a Capdevila, J. |b 1 |
| 700 | 1 | _ | |a Unger, N. |b 2 |
| 700 | 1 | _ | |a Fendler, W. |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Theurer, S. |b 4 |
| 700 | 1 | _ | |a Weber, F. |b 5 |
| 700 | 1 | _ | |a Fuhrer, D. |b 6 |
| 700 | 1 | _ | |a Lahner, H. |b 7 |
| 773 | _ | _ | |a 10.1530/ERC-25-0165 |g p. ERC-25-0165 |0 PERI:(DE-600)2010895-3 |n 8 |p e250165 |t Endocrine related cancer |v 32 |y 2025 |x 1351-0088 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:303371 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-17 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-17 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ENDOCR-RELAT CANCER : 2022 |d 2024-12-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-17 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-17 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-17 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|